Overview
Cybin is a clinical-stage neuropsychiatry company developing next-generation psychedelic therapeutics, including CYB003 (deuterated psilocin analog) in Phase 3 for adjunctive major depressive disorder (MDD) treatment and CYB004 (deuterated DMT) in Phase 2 for generalized anxiety disorder (GAD). The company partners with Thermo Fisher Scientific for U.S.-based Phase 3 clinical supply and commercial manufacturing of CYB003 capsules, and with Catalent for Zydis fast-dissolve formulation technology. Additional collaborations include Osmind for access to U.S. psychiatry clinics and real-world data.
Frequently asked questions
- What are Cybin's lead drug candidates and their development stages?
- CYB003, a proprietary deuterated psilocin analog, is in Phase 3 studies (APPROACH, EMBRACE, EXTEND) for adjunctive MDD treatment with ongoing dosing and ~550 patient enrollment. CYB004, a deuterated DMT, completed Phase 2 enrollment for GAD with topline data expected Q1 2026.
- Who are Cybin's key manufacturing and service partners?
- Thermo Fisher Scientific provides U.S.-based Phase 3 clinical supply and commercial manufacturing for CYB003 capsules. Catalent applies Zydis ODT technology for CYB003 delivery. Osmind offers access to 800+ U.S. psychiatry clinics and real-world data.
- What geographies does Cybin operate in for clinical trials?
- Cybin conducts trials primarily in the U.S., with Phase 3 CYB003 studies across 45 sites, Phase 2 CYB004 enrollment completed, and manufacturing partnerships focused on U.S.-based capabilities.